FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.
Related Articles
MAXILUS Study Looks to Further Elucidate the Role of Luspatercept in MDS
The MAXILUS study will evaluate the maximum approved dose of luspatercept in lower-risk myelodysplastic syndrome.
HPV Vaccines Not Cost Effective for Some
For adults ages 27 to 45, vaccinating against human papillomavirus (HPV) is costlier and less effective than vaccinating younger people to prevent HPV-related cancers (Ann…
Welcome! You are invited to join a webinar: SSO & ASTS Virtual Tumor Board: Transplant Oncology . After registering, you will receive a confirmation email about joining the webinar.
Welcome! You are invited to join a webinar: SSO & ASTS Virtual Tumor Board: Transplant Oncology . After registering, you will receive a confirmation email…
Matthias Guckenberger (@mguckenberger.bsky.social)
Passionate Radiation Oncologist Chairman University Hospital Zurich Professor University of Zurich President of ESTRO
UK SABR Consortium (@uksabr.bsky.social)
The SABR UK consortium’s official BlueSky account. Please follow us and share our BlueSky page! https://bsky.app/profile/uksabr.bsky.social
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Abstract. Antibody–drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than…
Program
Program for AACR Special Conference in Cancer Research: DNA Methylation, Clonal Hematopoiesis, and Cancer
Ovarian Toxicity in Premenopausal Adults
This guidance provides recommendations to sponsors regarding measurement of ovarian toxicity using clinical measures and biomarkers of ovarian function
An Assortment of Journal Abstracts to Enhance Oncology Care : Oncology Times
An abstract is unavailable.
Novel PI3Kα Inhibitor STX-478 Offers Precise Treatment and Reduced Toxicity for Solid Tumors
Alberto Montero, MD, MBA, discusses the importance of PI3Kα pathway inhibition in solid tumors and expands on the unique mechanism of action of STX-478.